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Abstract
Vascular calcification is implicated in the pathogenesis of atherosclerosis, diabetes and chronic kidney disease. Human vascular smooth muscle
cells (HSMCs) undergo mineralization in response to elevated levels of inorganic phosphate (Pi) in an active and well-regulated process. This
process involves increased activity of alkaline phosphatase and increased expression of core binding factor a-1 (CBF-a1), a bone-specific tran-
scription factor, with the subsequent induction of osteocalcin. It has been shown that heavy alcohol consumption is associated with greater cal-
cification in coronary arteries. The goal of our study was to examine whether ethanol alters mineralization of HSMCs provoked by high Pi.
Exposure of HSMCs to ethanol increased extracellular matrix calcification in a dose responsive manner, providing a significant additional cal-
cium deposition at concentrations of  60 mmol/l. HSMC calcification was accompanied by further enhancement in alkaline phosphatase activ-
ity. Ethanol also provoked a significant increase in the synthesis of osteocalcin. Moreover, in cells challenged with ethanol the expression of
CBF-a1, a transcription factor involved in the regulation of osteoblastic transformation of HSMCs, was elevated. The observed effects of ethanol
were not due to alterations of phosphate uptake by HSMCs. We conclude that ethanol enhances Pi-mediated human vascular smooth muscle
calcification and transition of these cells into osteoblast-like cells.
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Introduction
Vascular calcification is implicated in the pathogenesis of various vas-
cular diseases and can result in devastating clinical consequences. It
is related to an increased risk of cardiovascular morbidities and com-
plications such as atherosclerotic plaque burden [1–3], myocardial
infarction [4, 5], coronary artery disease [6, 7], postangioplasty dis-
section [8], and increased ischemic episodes in peripheral vascular
disease [9]. It has been shown to be a powerful independent marker
of coronary heart disease events in patients with diabetes [6]. Studies
also indicated that coronary calcification may be predictive of or asso-
ciated with sudden cardiac death [10, 11]. Recently it has been found
that cardioprotective effect of moderate alcohol consumption against
ischemic heart disease disappears when light to moderate drinking is
mixed with irregular heavy drinking occasions [12]. Moreover, there
is evidence that heavy consumption of hard liquor is associated with
greater accumulation of calcium in coronary artery [13]. Calciphylaxis
known to almost exclusively develop in patients with Stage 5 chronic
kidney disease (CKD) was also reported to occur in heavy drinkers
with physiological renal function [14–17].
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Although the mechanism of vascular calcification is not completely
understood, abnormalities in mineral metabolism are considered impor-
tant risk factors. Indeed, both the Framingham risk index and coronary
calcification score as measured by electron beam computed tomography
have been shown to have prognostic value for cardiovascular events
[11]. Strong associations between arterial calcification and stiffness,
pulse pressure, or mortality in dialysis patients have also been revealed
contributing to the high rates of cardiac and peripheral ischemic disease
and left ventricular hypertrophy in this population [18–20]. Many studies
have demonstrated the role of high extracellular Pi to induce vascular
calcification [21–24]. It has been revealed that phosphate uptake through
a sodium-dependent phosphate co-transporter, Pit-1 is essential for vas-
cular smooth muscle cell calcification and phenotypic modulation in
response to elevated phosphate [25]. Recently novel functions of Pit-1
related to cell signalling, cell proliferation and apoptosis were emerged
[26]. Transition of smooth muscle cells into osteoblast-like cells is a deli-
cate and well-regulated cellular process where cells gain an osteoblastic
phenotype. This is indicated by the increase in expression of CBF-a1
which is an osteoblast-specific transcription factor required for osteo-
blast differentiation, bone matrix gene expression, and consequently,
bone mineralization [27]. Upregulation of alkaline phosphatase, an
important enzyme in early osteogenesis and osteocalcin, a major noncol-
lagenous protein in bone matrix demonstrated to regulate mineralization,
was also shown to occur [28].
These previous studies prompted us to investigate the role that etha-
nol may play in vascular smooth muscle cell mineralization and transition
of smooth muscle cells into osteoblast-like cells in vitro. We observed
that ethanol at high concentration found in blood during heavy alcohol
consumption enhances Pi-provoked HSMC calcification leading to for-
mation of granular calcium deposits in extracellular matrix. Osteoblastic
transformation of HSMCs is promoted by ethanol as assessed by upreg-
ulation of CBF-a1, osteocalcin, and alkaline phosphatase.
Materials and methods
Cell culture and reagents
Human aortic smooth muscle cells were purchased from Cell Applica-
tions Inc. (San Diego, CA, USA) and FBS from Gibco (Paisley, UK).
Unless otherwise mentioned, all other reagents were obtained from
Sigma-Aldrich (Steinheim, Germany). Cell cultures were maintained in
growth medium DMEM (GM) containing 15% FBS, 60 U/ml penicillin,
60 lg/ml streptomycin and 120 lg/ml neomycin and 1 mM of sodium
pyruvate. Cells were grown to confluence and used from passages 3 to
7. HepG2 cells were maintained in DMEM containing 10% FBS, 100 U/
ml penicillin and 100 lg/ml streptomycin.
Induction of calcification
At confluence, cells were maintained in calcification medium which was
prepared by adding 1–4 mmol/l of Pi to the growth medium. Both
growth medium and calcification medium were changed every two days.
The enhancement of Pi-provoked calcification by ethanol was most pro-
nounced at a Pi concentration of 3 mmol/l. Therefore, we used 3 mmol/
l Pi for inducing calcification in our experiments.
Quantification of calcium deposition
Cells grown on 48 well plates were washed twice with PBS and decalci-
fied with 0.6 N HCl for 30 mins. Calcium content of the supernatants
was determined by the QuantiChrome Calcium Assay Kit (Gentaur,
Paris, France) as described by the protocol. After decalcification, cells
were washed twice with PBS and solubilized with NaOH (0.1 mol/l),
SDS (0.1%) and protein content of samples were measured with a BCA
protein assay kit (Thermo Scientific, Rockford, IL, USA). Calcium con-
tent of the cells was normalized to protein content and expressed as
lg/mg protein. Mineral deposition in the extracellular matrix was also
assessed by Alizarin Red staining [29]. After staining, cells were washed
twice with distilled water and once with 70% ethanol. To solubilize the
stained extracellular matrix granules we incubated the cells with
100 mmol/l cetylpyridinium chloride for 1 hr, followed by measuring
the absorbance of the dissolved dye at 570 nm.
Phosphate measurement
Pi content of cell lysate was determined by the QuantiChrome Phosphate
Assay Kit (Gentaur, Paris, France). After the ethanol treatment cells were
washed twice with PBS and solubilized with 1% Triton X-100 and the cell
lysates were assayed for Pi. Phosphate content of the cells was normal-
ized to protein content and expressed as mmol/mg cell protein [29].
Alkaline phosphatase (ALP) activity assay
Cells grown on 6-well plates were washed with HBSS twice, cellular
proteins were solubilized with 1% Triton X-100 in 0.9% NaCl and were
assayed for ALP activity. Briefly, 130 ll of Alkaline Phosphatase Yellow
Liquid Substrate (Sigma-Aldrich) was combined with 50 lg of protein
samples. Kinetics of p-nitrophenol formation was followed for 30 min.
at 405 nm during incubation at 37°C. Maximum slope of the kinetic
curves was used for calculation [29].
Western blot and osteocalcin assay
To detect osteocalcin expression cells grown on six-well plates were trea-
ted for 7 days. Extracellular matrix was dissolved in 200 ll of EDTA
(0.5 mol/l, pH 6.9) for osteocalcin then cell lysate was obtained for glyc-
eraldehyde-3-phosphate dehydrogenase. Equal loading of 30 ll EDTA sol-
ubilized sample was electrophoresed on a 16.5% Tris-Tricine Peptide gel
(Bio-Rad, Hercules, CA, USA), blotted onto nitrocellulose membrane (Hy-
bond-ECL; Amersham Biosciences, Buckinghamshire, UK). After blocking,
the membrane was incubated with polyclonal anti-osteocalcin antibody at
1:200 dilution (Santa Cruz, Santa Cruz, CA, USA), followed by a peroxi-
dase labelled anti-rabbit IgG antibody (Amersham Biosciences). For glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) 30 ll of cell lysate was
electrophoresed on a 12.5% SDS-PAGE then blotted onto a nitrocellulose
membrane. The membrane was incubated with mouse monoclonal
anti-GAPDH (Novus Biologicals, Inc., Cambridge, UK) followed by a per-
oxidase labelled antimouse IgG antibody (Amersham Biosciences). For
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alcohol dehydrogenase 1 cell lysate was electrophoresed on a 12.5%
SDS-PAGE and blotted onto nitrocellulose membrane. After blocking, the
membrane was incubated with rabbit monoclonal anti-alcohol dehydroge-
nase 1 antibody at 1:1000 dilution (Abcam, Cambridge, UK), followed by
a peroxidase labelled anti-rabbit IgG antibody. After detection, membrane
was reprobed for glyceraldehyde-3-phosphate dehydrogenase. Antigen-
antibody complex was visualized with the horseradish peroxidase chemi-
luminescence system according to the manufacturer’s instructions (Amer-
sham Biosciences). Quantification of proteins was performed with
computer-assisted videodensitometry (Alpha DigiDoc RT, Alpha Innotech,
San Leandro, CA, USA). Osteocalcin content of the same EDTA solubilized
extracellular matrix sample was quantified by an enzyme-linked immuno-
absorbent assay (Bender MedSystems, Vienna, Austria), according to the
manufacturer’s instructions.
Quantitative reverse transcription-polymerase
chain reaction
Total RNA was isolated, reverse transcribed and CBF-a1 mRNA was
determined as described previously [29, 30]. Briefly, for CBF-a1 mRNA
levels the 25 ll reaction mixture contained 5 ll of reverse transcribed
sample, 0.3 nmol/l of forward (5′-ATGGCGGGTAACGATGAAAAT-3′) and
reverse primers (5′-ACGGCGGGGAAGACTGTGC-3′) and 12.5 ll of iQ
SYBR Green Supermix (Bio-Rad). PCRs were carried out using the iCy-
cler iQ Real Time PCR System (Bio-Rad). Results were normalized by
Cyclophilin mRNA levels.
Cell viability assay
After treatment of cells with 20–80 mmol/l of ethanol in the presence
or absence of calcification medium for seven days we assessed cell via-
bility using PrestoBlue cytototoxicity assay (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s instructions.
Statistics
Data are shown as mean ± S.D. Statistical analysis was performed by
one-way ANOVA test followed by a Newmann-Keuls test for multiple com-
parison and two-way ANOVA test for Figure 1. A value of P < 0.05 was
considered significant and marked with *, and P < 0.01 was considered
highly significant and marked with **.
Results
Ethanol increases HSMC calcification in a dose
responsive manner
To develop an in vitro model of human vascular calcification, we cul-
tured HSMCs in calcification medium, which was prepared by the addi-
tion of 1–4 mmol/l of Pi to the growth medium. After culturing HSMC
in calcification medium for 7 days, extracellular calcium measurements
were performed in the presence or absence of ethanol (Fig. 1). As
expected, phosphate provoked calcification in a dose dependent manner,
providing a significant induction at a dose of 3 mmol/l and above.
Importantly, exposure of cells to 60 mmol/l of ethanol further
enhanced calcium deposition in HSMC culture. In contrast, ethanol
alone did not alter HSMC calcification for 14 days of incubation time
(data not shown). To confirm the additional enhancement in extracel-
lular calcium deposition provided by ethanol we performed Alizarin
Red staining of HSMCs cultured in calcification medium (Fig. 2). After
exposure of HSMCs from 20 to 80 mmol/l of ethanol for seven days,
more granular deposits developed throughout the cell culture
(Fig. 2A) compared to HSMCs cultured in ethanol free calcification
medium, whereas in the control culture, no deposits were found dur-
ing this period. Extracellular calcium measurements were carried out
to prove that phosphate-induced calcification is dose dependently fur-
ther increased by ethanol. As shown in Figure 2B and C, the facilitat-
ing effect of ethanol on extracellular calcification is dose dependent,
providing a significant additional increase in calcium deposition at a
concentration of  60 mmol/l.
Ethanol promotes the expression of alkaline
phosphatase activity in HSMCs
It has been demonstrated that vascular calcification in vivo shares
similarities with bone mineralization; therefore we asked the question
of whether ethanol fosters the transition of HSMCs into osteoblast-
like cells. Alkaline phosphatase (ALP) is an important enzyme in early
mineralization of bone and teeth. We therefore examined whether eth-
anol increases ALP activity in HSMCs maintained in calcification med-
ium (Fig. 3). While HSMCs cultured in calcification medium exhibited
a 1.61-fold increase in ALP activity, addition of 60 and 80 mmol/l eth-
anol to calcification medium resulted in further enhancement up to
2.17- and 2.12-fold, respectively. On the contrary, exposure of cells
Fig. 1 Ethanol promotes human vascular smooth muscle cell calcifica-
tion provoked by phosphate. Human vascular smooth muscle cells were
cultured in GM alone or in calcification medium containing 1–4 mmol/l
of phosphate. Media were supplemented with 60 mmol/l of ethanol. Cal-
cium content of cells was measured after 7 days of culture as described
in Materials and Methods, and was normalized by protein content. Data
are presented as the mean ± S.D. of three independent experiments
performed in duplicates. *P < 0.05, **P < 0.01.
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to ethanol failed to alter the expression of ALP in HSMCs maintained
in normal growth medium (data not shown).
Ethanol increases the synthesis of osteocalcin in
HSMCs
Next we investigated expression of another bone-specific gene,
osteocalcin. As demonstrated by the immunoblot in Figure 4B, higher
amounts of osteocalcin were present in the extracellular matrix of eth-
anol-treated HSMCs cultured in calcification medium as compared to
cells maintained in ethanol free calcification medium. Osteocalcin was
not detectable in the matrix of HSMCs cultured in normal growth
medium. Extracellular osteocalcin measurements were performed to
confirm that phosphate-induced transition of HSMCs into osteoblast-
like cells is dose-dependently promoted by ethanol. As shown in
Figure 4A and B, ethanol treatment of HSMCs maintained in a calcifi-
cation medium led to a more pronounced increase in osteocalcin
synthesis at a concentration of  60 mmol/l compared to HSMCs
cultured in ethanol free calcification medium. In contrast, treatment
of cells with ethanol did not increase the synthesis of osteocalcin in
HSMCs maintained in normal growth medium (data not shown).
Ethanol enhances the expression of osteoblast-
specific transcription factor CBF-a1
Transcription factor CBF-a1 is implicated in the osteoblastic differentia-
tion of vascular smooth muscle cells induced by high phosphate level.
Hence, we investigated if ethanol could alter the expression of CBF-a1 in
HSMCs maintained in calcification medium (Fig. 5), and therefore put
forward a possible explanation for the observed promoting effects of eth-
anol on transition of HSMCs into osteoblast-like cells. Culturing HSMCs
in a calcification medium for 24 hrs resulted in a 1.62-fold increase of
CBF-a1 mRNA level compared to cells maintained in a normal growth
medium. The addition of  60 mmol/l ethanol to the calcification
medium further enhanced the CBF-a1 mRNA level in HSMCs, although
ethanol in a normal growth medium failed to alter CBF-a1 expression.
The effect of ethanol on intracellular phosphate
level and cell viability
Because evidence suggests the effects of hyperphosphatemia are
mediated through a sodium-dependent phosphate co-transporter that
Fig. 2 Dose dependent effect of ethanol on human smooth muscle cell
calcification. (A) HSMCs were cultured in GM or in calcification medium
in the absence or presence of increasing concentration of ethanol for
7 days then Alizarin Red staining was performed. Representative images
of stained plates (upper) and microscopic views (9100, lower) from three
independent experiments are shown. (B) Quantification of Alizarin Red
staining after solubilization of granular deposits with cetylpyridinium chlo-
ride as described in Materials and Methods. (C) In the same experiments
extracellular calcium measurements were carried out using QuantiChrome
Calcium Assay. Data are presented as mean ± S.D. of three independent
experiments performed in duplicates. *P < 0.05, **P < 0.01.
Fig. 3 Ethanol enhances the expression of alkaline phosphatase activity
in human vascular smooth muscle cells. HSMCs were cultured in GM
or in calcification medium in the absence or presence of increasing con-
centration of ethanol for seven days. Alkaline phosphatase activity of
cells was measured as described in Materials and Methods. Data are
expressed as the means ± S.D. of six independent experiments each
performed in duplicates. *P < 0.05, **P < 0.01.
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facilitates entry of phosphate into vascular cells, we measured the
phosphate uptake of HSMCs after 24 hrs of incubation in a calcifica-
tion medium in the presence and absence of ethanol. Our results indi-
cate (Fig. 6A) that ethanol did not alter the elevation of intracellular
phosphate level in HSMCs that resulted from high extracellular phos-
phate concentration. To test the viability of cells challenged with etha-
nol in calcification medium, we performed a PrestoBlue assay. As
shown in Figure 6B, the calcification medium did not decrease the
viability of HSMCs. Furthermore, HSMCs exposed to 20–80 mmol/l of
ethanol in a calcification medium for seven days did not exhibit a
decline in cell viability.
Fig. 4 Ethanol increases the synthesis of osteocalcin in human vascular
smooth muscle cells. (A) After seven days culturing of HSMCs in GM
or calcification medium alone or supplemented with 20, 40, 60 and
80 mmol/l ethanol, the extracellular matrix was dissolved and osteocal-
cin deposition was quantified as described in Materials and Methods.
(B) Western blot analysis was performed and densitometric measure-
ment of the band intensities for osteocalcin and the corresponding GAP-
DH from cell monolayer were determined as described in Materials and
Methods. Data are expressed as the means ± S.D. of four independent
experiments. *P < 0.05, **P < 0.01.
Fig. 5 Ethanol enhances the expression of osteoblast-specific transcrip-
tion factor CBF-a1 in human vascular smooth muscle cells. HSMCs
were cultured in GM or in calcification medium alone or in the presence
of ethanol (20, 40, 60 and 100 mmol/l) for 24 hrs. CBF-a1 mRNA levels
were determined by quantitative RT-PCR as described in Materials and
Methods. Results are presented as the mean ± S.D. of three indepen-
dent experiments performed in triplicates. *P < 0.05, **P < 0.01.
Fig. 6 Ethanol does not alter phosphate entry into human vascular
smooth muscle cells. (A) HSMCs were cultured in GM or calcification
medium alone or supplemented with ethanol (20, 40, 60, 80 mmol/l)
for 24 hrs. Cell lysate was used to measure Pi levels as described in
Materials and Methods. Results are presented as the mean ± S.D. of
six independent experiments performed in duplicates. (B) For investiga-
tion of whether ethanol causes significant toxicity a PrestoBlue assay
was performed after seven day of incubation. Data are the means ±
S.D. of four separate experiments in duplicates. *P < 0.05, **P < 0.01.
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Alcohol dehydrogenase 1 is not detectable in
HSMCs
Because metabolism of ethanol by alcohol dehydrogenase occurs in
cells including hepatocytes generating acetaldehyde, we assessed its
expression in HSMCs. Employing Western blot analysis alcohol dehy-
drogenase 1 was not detectable in HSMCs regardless their exposure
to ethanol (Fig. 7). As shown in Figure 7, there was a marked protein
expression in a human-derived hepatoma line (HepG2 cells).
Discussion
Mineralization in soft tissues develops under pathological conditions
and has detrimental consequences, particularly when it occurs within
vessel walls and heart valves. Elevated phosphate level has long been
recognized to highly correlate with vascular calcification in patients
with Stage 5 CKD [31–33]. In fact, the major cause of mortality in
patients requiring haemodialysis is cardiovascular events. In particu-
lar, the development of calciphylaxis, which is a syndrome of vascular
calcification and skin necrosis, is almost exclusively seen in patients
with Stage 5 CKD and correlates with extremely high fatality rates.
Previous studies indicated that elevated phosphate could induce
smooth muscle cell calcification, as well as an osteochondrogenic
phenotypic change in vitro [34]. Evidence suggests a highly regulated
cellular process where many different inducers and inhibitors of
osteoblast differentiation have been recognized [35]. These studies
have demonstrated an in vitro model where HSMCs cultured with cal-
cification medium containing high levels of phosphate not only
undergo mineralization, but also manifest upregulation of osteoblast
markers [24, 25, 27, 28]. These include CBF-a1, a key regulatory
transcription factor critical for the differentiation of osteoblasts, and
its downstream transcript proteins such as ALP, a crucial enzyme in
the context of bone and teeth formation, and osteocalcin, which is a
very specific protein indicative of osteoblast activity. CBF-a1 knockout
mice fail to form mineralized bone [36] and exhibit low ALP activity
and osteocalcin expression.
Alcohol consumption has been consistently found to have a J-
shaped association with coronary heart disease – moderate drinkers
have a lower risk than both heavy and non-drinkers. This relationship
has not been studied extensively across races or ethnicities, but
evidence to date consistently shows a protective effect [37–39]. A
recent study confirmed that moderate alcohol use has an apparent
protective association with coronary heart disease [13]. However, the
authors found no evidence of such a protective association of alcohol
consumption and coronary artery calcification. In fact, they reported
evidence that heavy alcohol consumption, in particular hard liquor, is
associated with greater calcification in coronary arteries.
Calciphylaxis was reported to occur in patients diagnosed with
alcoholic liver disease who did have physiological renal function and
calcium-phosphate metabolism [14–16]. Possible contributing fac-
tors were suggested to be protein C and protein S deficiencies due to
the liver disease. Calciphylaxis was also reported in alcoholic cardio-
myopathy in patients who did not develop liver and kidney disease
and any alteration in calcium-phosphate metabolism [17].
These studies prompted us to investigate whether or not ethanol
promotes vascular smooth muscle cell mineralization and its transi-
tion into osteoblast-like cells in vitro. Importantly, in the present
study, the addition of ethanol to the calcification medium enhanced
HSMC mineralization in a dose responsive manner. The elevated
phosphate-induced calcification was further increased providing a
significant additional extracellular calcium accumulation at dose of
 60 mmol/l – such concentrations can be observed in heavy drink-
ers’ blood. Because ALP is an important enzyme in the mineralization
process and osteocalcin, a non-collagenous calcium binding protein,
is specific for osteoblast phenotype, we also examined whether etha-
nol increases ALP activity and synthesis of osteocalcin in HSMCs.
Ethanol provoked a significant increase in the expression of ALP and
osteocalcin. Moreover, in cells challenged with ethanol the expression
of CBF-a1, a transcription factor involved in the regulation of osteo-
blastic transformation of HSMCs, was also elevated. It has been
established that osteoblastic differentiation induced by hyperphos-
phatemia is mediated via a sodium-dependent co-transporter (Pit-1)
that facilitates entry of phosphate into vascular cells [25]; therefore,
we measured phosphate uptake. Our results demonstrate that the
observed effects of ethanol are not due to alterations of phosphate
uptake.
There is extensive in vitro evidence that apoptosis of HSMCs can
promote calcification in vessels, which is seen both in the intima in
advanced plaques and in the media in CKD. Apoptotic smooth muscle
cells may act as both a nidus for calcification, and actively concentrate
both calcium and phosphate to generate hydroxyapatite [40–42].
In fact, alcohol-induced apoptosis of vascular smooth muscle cells
was recently demonstrated to occur [43] although we did not observe
significant decline in viability of HSMCs in our experiments.
In a study by Giachelli’s group osteoblastic transformation of vas-
cular smooth muscle cells was elegantly demonstrated to be revers-
ible [44]. They found that vascular cells with osteochondrogenic
phenotype regain smooth muscle cell properties and down-regulated
osteochondrogenic gene expression in environment that favours vas-
cular smooth muscle cells. Runx2/CBF-a1 was shown to be a decisive
factor in the smooth muscle cell reprogramming. Therefore, we also
need to answer in future whether or not mineralization of HSMCs pro-
moted by ethanol is reversible.
Fig. 7 Alcohol dehydrogenase 1 is not detectable in human vascular
smooth muscle cells. After seven days culturing of HSMCs, human
umbilical vein endothelial cells (HUVEC) and HepG2 cells in medium
alone or supplemented with 60 mmol/l ethanol, Western blot analysis
was performed for alcohol dehydrogenase 1 (ADH1). Membrane was
reprobed for GAPDH as described in Materials and methods.
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Ethanol is metabolized in the liver mainly by the action of alcohol
dehydrogenase 1 leading to the generation of acetaldehyde. Thus,
acetaldehyde if produced by alcohol dehydrogenase 1 in HSMCs was
a possible contributing factor to the HSMC mineralization in our
model. Therefore we measured the expression of alcohol dehydroge-
nase 1 in vascular smooth muscle cells. Using Western blot analysis
alcohol dehydrogenase 1 was not detectable in HSMCs indicating that
acetaldehyde did not act as a promoter in mineralization induced by
ethanol.
In conclusion, our results suggest that HSMC mineralization and
transition into osteoblast-like cells induced by ethanol may contribute
to greater vascular calcification observed in heavy alcohol consump-
tion. It also offers an alternative explanation as to why calciphylaxis
occurs in heavy drinkers without kidney diseases and any alterations
in calcium-phosphate metabolism. This study may have relevance in
CKDs in which high alcohol consumption might assist vascular calci-
fication.
Acknowledgements
The research group is supported by the Hungarian Academy of Sciences. This
work was supported by Hungarian Government grants OTKA-K75883 (Gy.B.),
OTKA-K83478 (J.B.), OTKA-NK72730 (L.N), OTKA-K72315 (A.T.) OTKA-
PD83435 (V.J.), ETT-147/2009 (Gy.B.), MTA-DE-11003 (J.B.), Janos Bolyai
Scholarship of the Hungarian Academy of Sciences (I.L.), European Reintegra-
tion Grant FP7-PEOPLE-2010-268332 (V.J.), and by the TA´MOP 4.2.1./B-09/1/
KONV-2010-0007 (J.B., Gy.B, L.N., A.T.) TA´MOP-4.2.2/B-10/1-2010-0024 (L.
N., A.T.) projects. The project is implemented through the New Hungary Devel-
opment Plan, co-financed by the European Union and the European Social
Fund.
Conflict of interest
The authors confirm that there are no conflicts of interest.
References
1. Block GA, Port FK. Re-evaluation of risks
associated with hyperphosphatemia and
hyperparathyroidism in dialysis patients:
recommendations for a change in man-
agement. Am J Kidney Dis. 2000; 35:
1226–37.
2. Rumberger JA, Simons DB, Fitzpatrick LA,
et al. Coronary artery calcium area by elec-
tron-beam computed tomography and coro-
nary atherosclerotic plaque area. A
histopathologic correlative study. Circula-
tion. 1995; 92: 2157–62.
3. Sangiorgi G, Rumberger JA, Severson A,
et al. Arterial calcification and not lumen
stenosis is highly correlated with atheroscle-
rotic plaque burden in humans: a histologic
study of 723 coronary artery segments
using nondecalcifying methodology. J Am
Coll Cardiol. 1998; 31: 126–33.
4. Beadenkopf WG, Daoud AS, Love BM. Calci-
fication in the Coronary Arteries and Its
Relationship to Arteriosclerosis and Myocar-
dial Infarction. Am J Roentgenol Radium
Ther Nucl Med. 1964; 92: 865–71.
5. Loecker TH, Schwartz RS, Cotta CW, et al.
Fluoroscopic coronary artery calcification
and associated coronary disease in asymp-
tomatic young men. J Am Coll Cardiol. 1992;
19: 1167–72.
6. Lehto S, Niskanen L, Suhonen M, et al.
Medial artery calcification. A neglected har-
binger of cardiovascular complications in
non-insulin-dependent diabetes mellitus. Ar-
terioscler Thromb Vasc Biol. 1996; 16: 978–
83.
7. Olson JC, Edmundowicz D, Becker DJ,
et al. Coronary calcium in adults with type 1
diabetes: a stronger correlate of clinical cor-
onary artery disease in men than in women.
Diabetes. 2000; 49: 1571–8.
8. Fitzgerald PJ, Ports TA, Yock PG. Contribu-
tion of localized calcium deposits to dissec-
tion after angioplasty. An observational
study using intravascular ultrasound. Circu-
lation. 1992; 86: 64–70.
9. Niskanen LK, Suhonen M, Siitonen O, et al.
Aortic and lower limb artery calcification in
type 2 (non-insulin-dependent) diabetic
patients and non-diabetic control subjects. A
five year follow-up study. Atherosclerosis.
1990; 84: 61–71.
10. Burke AP, Taylor A, Farb A, et al. Coronary
calcification: insights from sudden coronary
death victims. Z Kardiol. 2000; 89: 49–53.
11. Taylor AJ, Burke AP, O’Malley PG, et al. A
comparison of the Framingham risk index,
coronary artery calcification, and culprit pla-
que morphology in sudden cardiac death.
Circulation. 2000; 101: 1243–8.
12. Roerecke M, Rehm J. Irregular heavy drink-
ing occasions and risk of ischemic heart
disease: a systematic review and meta-
analysis. Am J Epidemiol. 2009; 171: 633–
44.
13. McClelland RL, Bild DE, Burke GL, et al.
Alcohol and coronary artery calcium preva-
lence, incidence, and progression: results
from the Multi-Ethnic Study of Atherosclero-
sis (MESA). Am J Clin Nutr. 2008; 88: 1593–
601.
14. Lim SP, Batta K, Tan BB. Calciphylaxis in a
patient with alcoholic liver disease in the
absence of renal failure. Clin Exp Dermatol.
2003; 28: 34–6.
15. Goli AK, Goli SA, Shah LS, et al. Calciphy-
laxis: a rare association with alcoholic cir-
rhosis. Are deficiencies in protein C and S
the cause? South Med J. 2005; 98: 736–9.
16. Ferreres JR, Marcoval J, Bordas X, et al.
Calciphylaxis associated with alcoholic cir-
rhosis. J Eur Acad Dermatol Venereol. 2006;
20: 599–601.
17. Almafragi A, Vandorpe J, Dujardin K. Calci-
phylaxis in a cardiac patient without renal
disease. Acta Cardiol. 2009; 64: 91–3.
18. Guerin AP, Blacher J, Pannier B, et al.
Impact of aortic stiffness attenuation on sur-
vival of patients in end-stage renal failure.
Circulation. 2001; 103: 987–92.
19. Blacher J, Guerin AP, Pannier B, et al. Arte-
rial calcifications, arterial stiffness, and car-
diovascular risk in end-stage renal disease.
Hypertension. 2001; 38: 938–42.
20. London GM, Blacher J, Pannier B, et al.
Arterial wave reflections and survival in end-
stage renal failure. Hypertension. 2001; 38:
434–8.
21. Giachelli CM, Jono S, Shioi A, et al. Vascu-
lar calcification and inorganic phosphate.
Am J Kidney Dis. 2001; 38: S34–7.
22. Giachelli CM. Vascular calcification: in vitro
evidence for the role of inorganic phosphate.
J Am Soc Nephrol. 2003; 14: S300–4.
23. Shioi A, Nishizawa Y, Jono S, et al. Beta-
glycerophosphate accelerates calcification in
cultured bovine vascular smooth muscle
cells. Arterioscler Thromb Vasc Biol. 1995;
15: 2003–9.
24. Jono S, McKee MD, Murry CE, et al. Phos-
phate regulation of vascular smooth muscle
cell calcification. Circ Res. 2000; 87: E10–7.
ª 2012 The Authors 2225
Journal of Cellular and Molecular Medicine ª 2012 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
J. Cell. Mol. Med. Vol 16, No 9, 2012
25. Li X, Yang HY, Giachelli CM. Role of the
sodium-dependent phosphate cotransporter,
Pit-1, in vascular smooth muscle cell calcifi-
cation. Circ Res. 2006; 98: 905–12.
26. Lau WL, Festing MH, Giachelli CM. Phos-
phate and vascular calcification: Emerging
role of the sodium-dependent phosphate co-
transporter PiT-1. Thromb Haemost. 2010;
104: 464–70.
27. Otto F, Thornell AP, Crompton T, et al.
Cbfa1, a candidate gene for cleidocranial
dysplasia syndrome, is essential for osteo-
blast differentiation and bone development.
Cell. 1997; 89: 765–71.
28. Giachelli CM, Steitz S, Jono S. Potential
roles of bone matrix proteins in vascular cal-
cification. Clin Calcium. 1999; 9: 20–7.
29. Zarjou A, Jeney V, Arosio P, et al. Ferritin
prevents calcification and osteoblastic differ-
entiation of vascular smooth muscle cells. J
Am Soc Nephrol. 2009; 20: 1254–63.
30. Zarjou A, Jeney V, Arosio P, et al. Ferritin
ferroxidase activity: a potent inhibitor of
osteogenesis. J Bone Miner Res. 2010; 25:
164–72.
31. Block GA. Prevalence and clinical conse-
quences of elevated Ca x P product in he-
modialysis patients. Clin Nephrol. 2000; 54:
318–24.
32. Burke SK. Phosphate is a uremic toxin. J
Ren Nutr. 2008; 18: 27–32.
33. Block GA, Klassen PS, Lazarus JM, et al.
Mineral metabolism, mortality, and morbid-
ity in maintenance hemodialysis. J Am Soc
Nephrol. 2004; 15: 2208–18.
34. Steitz SA, Speer MY, Curinga G, et al.
Smooth muscle cell phenotypic transition
associated with calcification: upregulation of
Cbfa1 and downregulation of smooth muscle
lineage markers. Circ Res. 2001; 89: 1147–54.
35. Giachelli CM. Ectopic calcification: gather-
ing hard facts about soft tissue mineraliza-
tion. Am J Pathol. 1999; 154: 671–5.
36. Komori T, Yagi H, Nomura S, et al. Tar-
geted disruption of Cbfa1 results in a com-
plete lack of bone formation owing to
maturational arrest of osteoblasts. Cell.
1997; 89: 755–64.
37. Mukamal KJ, Chung H, Jenny NS, et al.
Alcohol consumption and risk of coronary
heart disease in older adults: the Cardiovas-
cular Health Study. J Am Geriatr Soc. 2006;
54: 30–7.
38. Kabagambe EK, Baylin A, Ruiz-Narvaez E,
et al. Alcohol intake, drinking patterns, and
risk of nonfatal acute myocardial infarction
in Costa Rica. Am J Clin Nutr. 2005; 82:
1336–45.
39. Yuan JM, Ross RK, Gao YT, et al. Follow up
study of moderate alcohol intake and mortal-
ity among middle aged men in Shanghai,
China. BMJ. 1997; 314: 18–23.
40. Clarke M, Bennett M. The emerging role of
vascular smooth muscle cell apoptosis in
atherosclerosis and plaque stability. Am J
Nephrol. 2006; 26: 531–5.
41. Proudfoot D, Skepper JN, Hegyi L, et al.
Apoptosis regulates human vascular calcifi-
cation in vitro: evidence for initiation of vas-
cular calcification by apoptotic bodies. Circ
Res. 2000; 87: 1055–62.
42. Proudfoot D, Davies JD, Skepper JN, et al.
Acetylated low-density lipoprotein stimulates
human vascular smooth muscle cell calcifi-
cation by promoting osteoblastic differentia-
tion and inhibiting phagocytosis. Circulation.
2002; 106: 3044–50.
43. Li W, Li J, Liu W, et al. Alcohol-induced
apoptosis of canine cerebral vascular
smooth muscle cells: role of extracellular
and intracellular calcium ions. Neurosci Lett.
2004; 354: 221–4.
44. Speer MY, Li X, Hiremath PG, et al. Runx2/
Cbfa1, but not loss of myocardin, is required
for smooth muscle cell lineage reprogram-
ming toward osteochondrogenesis. J Cell
Biochem. 2010; 110: 935–47.
2226 ª 2012 The Authors
Journal of Cellular and Molecular Medicine ª 2012 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
